Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06522737
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-22
Brief Title:
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With RelapsedRefractory Nodal T Cell Lymphoma With T Follicular Helper TFH Phenotype
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Multicentre Open-label Phase 3 Randomised Controlled Trial of Duvelisib Versus Investigators Choice of Gemcitabine or Bendamustine in Patients With RelapsedRefractory Nodal T Cell Lymphoma With T Follicular Helper TFH Phenotype
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TERZO
Brief Summary:
The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigators choice of gemcitabine or bendamustine in participants with relapsedrefractory nodal T cell lymphoma with TFH phenotype
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None